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Therapy of Wilson’s disease continues to evolve. In 1997,
zinc acetate was added to the list of drugs approved by the
Food and Drug Administration, which includes penicilla-
mine and trientine. The mechanism of zinc’s anticopper
action is unique. It induces intestinal cell metallothionein,
which binds copper and prevents its transfer into blood. As
intestinal cells die and slough, the contained copper is elimi-
nated in the stool. Thus, zinc prevents the intestinal absorption
of copper. It is universally agreed that pregnant Wilson’s
disease patients should remain on anticopper therapy during
pregnancy. There are numerous reports of such patients
stopping penicillamine therapy to protect their fetus from
teratogenicity, only to undergo serious deterioration and
even death from renewed copper toxicity. Penicillamine and
trientine have teratogenic effects in animals, and penicilla-
mine has known teratogenic effects in humans. In this report we
discuss the results of 26 pregnancies in 19 women who were on
zinc therapy throughout their pregnancy. The evidence is
good that zinc protects the health of the mother during
pregnancy. Fetal outcomes were generally quite good,
although one baby had a surgically correctable heart defect
and one had microcephaly. (HEPATOLOGY 2000;31:364-370.)
Wilson’s disease is a rare autosomal recessive disorder in
which copper accumulates, eventually leading to liver dis-
ease, and in some patients neurological disease manifesting as
a movement disorder, often complicated by behavioral distur-
bances.1 Patients generally become ill in their late teenage
years or early twenties, although age of onset can be quite
broad, ranging from early childhood into the fifties. After
diagnosis of an index case, siblings are screened, with 25%,
on average, being affected but in a ‘‘presymptomatic’’ state.
The disease is caused by mutation in a gene called ATP7B
producing a copper-binding adenosine triphosphatase, ex-
pressed in the liver and a few other tissues.2-4 Homozygosity
or compound heterozygosity for defects in this gene lead to a
failure of the liver to excrete copper in the bile destined for
loss in the stool.5-8 This excretion is necessary to maintain a
neutral copper balance. An epistatic effect of this genetic
defect is usually a low blood ceruloplasmin. Ceruloplasmin is
a copper-containing molecule synthesized in large amounts
by the liver and may be the copper-packaging, protease-
resistant molecule that is excreted into the bile to get rid of
excess copper via the stool.9 Thus, if ATP7B results in an
immature ceruloplasmin (for example without copper), the
genetic defect in Wilson’s disease could result in both a failure
of ceruloplasmin secretion into blood and excretion into bile.
Wilson’s disease is effectively treated by three U.S. Food
and Drug Administration–approved anticopper agents, which
include zinc,1 penicillamine,10 and trientine.11 In January,
1997 the Food and Drug Administration approved zinc for
the maintenance therapy of Wilson’s disease, based on our
work in developing this therapy.1,12-28 Schouwink29 and
Hoogenraad et al.30-32 have also used zinc to treat Wilson’s
disease. Because zinc is essentially nontoxic, and the other
two agents have toxic side-effects, in our opinion zinc is now
the preferred maintenance therapy for Wilson’s disease.
There are no contraindications to pregnancy in Wilson’s
disease during maintenance therapy, with the exception of
the presence of severe liver disease. However, it is very
important that treatment of Wilson’s disease with anticopper
agents continues during pregnancy.1,27,33 In the past, a num-
ber of pregnant women have stopped penicillamine during
pregnancy, knowing it is teratogenic. There are numerous
reports of such women suffering from severe regression of
their disease, often ending in death.33-36
Of the 3 anticopper agents available for treatment during
pregnancy, we favor zinc. Penicillamine is teratogenic in
animals37 and produces a teratogenic syndrome in human
babies.38-40 Trientine is teratogenic in animal studies.41,42 Zinc
has been studied for teratogenicity and is not teratogenic.43
This report discusses our experience in treating women with
Wilson’s disease with zinc during pregnancy.
MATERIALS AND METHODS
The pregnant patients primarily came from the large group of
Wilson’s disease patients we have been following for the develop-
ment of zinc therapy.27 Every patient from this group who became
pregnant was included in the study. In addition, there were 2
patients not from our group of patients who contacted us to go on
zinc during pregnancy. Through their physicians we managed zinc
therapy in these two using an ‘‘off-site protocol.’’
The diagnosis of Wilson’s disease was established by previously
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published methods.12-16 Table 1 provides basic data on the 19
women who were involved in the 26 live birth pregnancies. Two of
the women were Hispanic and accounted for 4 pregnancies. One
woman was Asian, 1 was East Indian, and the rest were Caucasian
(Table 1). Seven of the 19 women, accounting for 10 pregnancies,
were classified as presymptomatic, meaning that they were diag-
nosed before presenting clinically. Eight of the patients had pre-
sented neurologically, and 3 had presented with liver disease (Table
1). We do not know the clinical classification of 1 off-site patient
(patient 314).
Many of the patients had been on zinc for a long time before the
pregnancy (Table 1). In 11 pregnancies, prior zinc treatment was
over 5 years. In 18 of the pregnancies, the women were on 50 mg of
zinc 3 (or 2) times a day at the start, whereas 6 were on 25 mg of zinc
3 (or 2) times a day. Two patients were on penicillamine and were
switched to zinc during the second month of pregnancy (Table 1).
The 25- and 50-mg zinc acetate capsules used in this study were
compliments of Gate Pharmaceutical Co. (Montgomeryville, PA),
whose product is named Galzin. Urine, plasma, and liver copper and
zinc concentrations were measured by previously published meth-
ods.12-16 The protocol and consent procedures used in this study
were approved by the Institutional Review Board of the University of
Michigan. Each patient in this study was fully informed about the
project and gave written consent.
Liver function tests on blood samples were performed by standard
methods in the clinical biochemistry laboratory of the University of
Michigan Hospital. Quantitative neurological and speech scores
were determined by previously published methods.44
RESULTS
The primary monitoring tool of copper status we use while
patients are on zinc therapy is 24-hour urine copper (Table
2). This has the advantage that it can be monitored fairly
frequently, even at long distance, because a mail-in system is
used, and in our experience, 24-hour urine copper is the
single best monitoring tool for zinc therapy. The noncerulo-
plasmin plasma copper can also be used for monitoring if the
patients are available for taking blood samples, but in this
study, they were not available. Table 2 shows first the urine
copper that was done closest to the time before pregnancy
began. Based on experience, 24-hour urine copper values of
0.125 mg or less indicate adequate control of copper status
(0.02 to 0.05 mg is the normal range). It can be seen from the
second column of Table 2 that most of our patients had good
control of copper before pregnancy, although in some cases
the closest study was many months before pregnancy (col-
umn 3). An exception is patient 38. We had actually
discharged her from our patient study group because of
noncompliance and her habit of taking mineral supplements
that included copper. We did provide her with zinc to take
during pregnancy, and she agreed to provide information
about the pregnancy outcome. As can be seen from Table 2,
we were unable to obtain urine copper samples during or
after pregnancy in patient 38, although we did get a verbal
report from her obstetrician that she delivered a healthy
full-term baby. The 2 patients at the bottom of Table 2 are
‘‘off-site’’ patients, that is patients who did not come to the
University of Michigan to visit us. Both were on penicilla-
mine, became pregnant, and they and their doctors requested
our help in getting them on zinc therapy during pregnancy.
We supplied zinc for these patients during pregnancy. Patient
























27 H P 19 19 33 1 29.0 10.1 50 3 3
2 31.0 12.2 50 3 3
32 H P 23 23 37 1 25.2 1.8 50 3 3
2 25.8 2.4 50 3 3
34 C N 20 29 42 1 35.8 6.7 50 3 3
38 C N 20 21 34 1 32.4 11.5 50 3 3
41 C N 20 20 34 1 34.3 13.7 25 3 3
45 C P 26 27 39 1 28.7 1.5 50 3 3
2 31.5 4.4 50 3 2
49 C N 17 24 36 1 27.0 2.5 50 3 3
2 31.7 7.3 25 3 3
52 C N 24 27 37 1 29.2 2.6 50 3 3
2 30.4 3.9 25 3 3
57 C P 26 27 37 1 31.8 4.8 50 3 2
70 C H 10 19 28 1 21.2 2.5 50 3 3
2 25.2 6.5 50 3 3
86 C H 17 32 40 1 39.3 7.3 50 3 3
113 C H 20 26 32 1 31.4 5.2 25 3 3
2 33.0 6.2 25 3 3
130 C P 28 32 38 1 37.8 5.3 25 3 2
172 C N 20 20 24 1 24.2 4.0 50 3 3
173 C N 21 21 25 1 25.7 4.0 50 3 3
180 C N 25 29 32 1 33.2 3.0 50 3 3
204 EI P 27 28 31 1 31.2 3.5 50 3 3
312 C P 10 29 33 1 30.1 0.7 Pen
314 A 1 Pen
Abbreviation: Pen, penicillamine.
*H, Hispanic; C, Caucasian; A, Asian; EI, East Indian.
†P, presymptomatic; N, neurological; H, hepatic.
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312 provided interim and postpregnancy urine samples,
whereas patient 314 did not.
To evaluate the control of copper status during pregnancy
in these patients, it is useful to use Tables 2 and 3 together.
Table 3 provides zinc dose information. Our standard recom-
mended adult maintenance dose is 50 mg of zinc 3 times daily
(50 3 3). In many cases we tried to use a dose of 25 mg of
zinc 3 times daily (25 3 3) during pregnancy, with the
rationale that that was the minimally effective adult dose,20,27
and carried, theoretically, the least risk to the fetus. The
following patients were treated through more than half of
their pregnancy with this dose or lower (Table 3): patient 27,
pregnancies 1 and 2; patient 32, pregnancy 2; patients 34 and
41; patient 45, pregnancies 1 and 2; patient 49, pregnancy 1;
patient 52, pregnancies 1 and 2; patient 57; patient 113,
pregnancies 1 and 2; patient 130, 312, and 314. This is a total
of 16 pregnancies. Examining the urine copper data of Table
2 in these patients, we see that the following patients
remained well controlled on this dose: patient 27, pregnancy
1; patient 32, pregnancy 2; patient 41; patient 45, both
pregnancies; patient 49; patient 52, both pregnancies; patient
57; patient 113, both pregnancies; and patient 130, for a total
of 12 of the 15 on whom we have data (no data on patient
314). Patient 27 during pregnancy 2 had a urine copper of
0.163 mg in month 8, which was higher than we like to see.
However, her urine zinc value was 3.5 mg/24 hours (we view
any level over 2.0 mg as indicating adequate zinc therapy and
compliance), and we did not change her dose. Patient 312
had a urine copper of 0.318 mg at month 7, and although her
urine zinc was 4.1 mg, we increased her zinc dose. Other data
pertinent to using a lower zinc dose range during pregnancy
included patient 32, pregnancy 1. We decreased her dose to
25 3 2 at month 3, and had to increase it to 50 3 3 at month 7
when her urine copper came back at 0.226 mg in association
with an inadequate urine zinc of 0.8 mg. Patient 34 went on a
dose of 25 3 3 at month 2, and at month 9 showed a urine
copper of 0.222 mg, well above desired limits, but her urine
zinc was 4.2 mg, and we did not increase the dose. The
change in dose in patient 49, pregnancy 2, had nothing to do
with a change in copper status. In summary, in 4 of 16 cases
(where we have urine copper data) on lower doses of zinc,
urine copper values were higher than desired, and in 2
patients we felt we had to increase the dose to 50 3 3 during
pregnancy to regain control of copper status (patients 312
and 32). The increase in urine copper in patient 32 appears to
be caused by noncompliance, while in patient 312, compli-
ance, based on urine zinc at the time of sample submission,
seems to have been adequate. However, the margin for error
with noncompliance is much smaller on a dose of 25 3 3 than
it is on 50 3 3.
Patients primarily on a dose of 50 3 3 during pregnancy
included patient 70, both pregnancies; and patients 86, 172,
173, 180, and 204 (we don’t include 38 because of lack of
data). These patients did well in terms of copper control















Delivery1 2 3 4 5 6 7 8 9
27 0.084 7 0.108 0.043 2
0.043 14 0.163 0.072 2
32 0.128 0.073 0.226* 0.131 7
0.190 10 0.094 0.180 24
34 0.062 7 0.070 0.128 0.222 0.092 4
38 0.451 21
41 0.048 0 0.073 0.060 0.090 † †
45 0.058 1 0.099 0.089 0.092 0.038 3
0.053 6 0.068 0.073 0.075 1
49 0.075 1 0.073 0.101 0.083 3
0.089 2 0.115 0.106 0.085 4
52 0.087 6 0.051 0.073 0.026 3
0.026 2 0.084 0.067 2
57 0.053 5 0.059 0.050 0.051 2
70 0.084 11 0.139 0.098 0.182 0.302 6
0.086 3 0.045 8
86 0.165 4 0.045 0.073 3
113 0.025 2 0.075 0.067 0.054 2
0.025 2 0.101 0.062 0.084 0.053 2
130 0.056 2 0.109 0.133 0.106 0.111 0.086 1
172 0.067 1 0.067 0.087 † †
173 0.058 1 0.081 0.042 0.066 1
180 0.055 18 0.044 0.059
204 0.108 3 0.039 0.110 0.093 2
312 0.127 0.318* 0.192 0.064 3
314
MEAN 0.091 5.609 0.105 0.062 0.093 0.075 0.083 0.074 0.111 0.132 0.138 0.085 4.048
SD 0.085 5.562 0.035 0.025 0.019 0.007 0.029 0.018 0.041 0.035 0.059 0.059 4.825
N 24 23 2 7 8 3 9 5 4 6 3 21 21
*Increased dose to 50 3 3.
†Newborn at time of submission, data not yet available.
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while on this dose, although patient 70, pregnancy 1, had a
urine copper value of 0.139 and 0.182 at months 1 and 7,
respectively. We suspect problems with compliance in this
patient because her urine zinc values were 0.9 mg and 2.6 mg,
respectively.
Table 4 presents data on the preservation of the mother’s
liver function, and if relevant, neurological function, during
pregnancy. Table 4 presents the closest liver and neurological
function data available, before and after the pregnancies.
Because many of these patients were followed at long
distance, the data are not as comprehensive as the urine data,
which were usually obtained from mail-in samples. Before
and after liver function data were collected on 10 women
involving 15 pregnancies, and show stability in the mothers’
liver function (Table 4). Neurological and/or speech scores
were collected on 3 women who had presented with neurologi-
cal disease, totaling 5 pregnancies, and again showed func-
tional stability.
Table 5 presents a summary of fetal outcome, with one
major (microcephaly) and one minor fetal (surgically correct-
able heart defect) abnormality among the 26 live births.
Average urine copper values during pregnancy, and the
patients’ rank in urine copper, from highest to lowest, are also
shown. We are aware of 4 miscarriages (not reported here).
DISCUSSION
When choosing or recommending an anticopper therapy
for a Wilson’s disease patient during pregnancy, a physician
must consider both sustaining the health of the mother, and
the avoidance of teratogenicity in the fetus. It is clear that
anticopper therapy must continue during pregnancy. Patients
who have discontinued penicillamine therapy to avoid birth
defects in a child have experienced serious remission of
Wilson’s disease, including death.33-36
There is considerable experience with penicillamine treat-
ment during pregnancy, and if taken properly, it appears to
sustain the mother’s health, and keep her Wilson’s disease
under control.33,35,36 However, penicillamine is associated with
significant teratogenicity in both animals and humans.37-39,42
In the human it produces a cutis laxis syndrome, which in its
severe form can resemble Ehlers-Danlos syndrome, or pro-
duce micrognathia, low set ears, and other abnormalities.
Rosa40 has concluded that, ‘‘the available evidence suggests
that a prudent course for conditions for which there are safer
alternatives would be to discontinue penicillamine during
pregnancy.’’
With penicillamine falling into some disfavor for use
during pregnancy because of its teratogenic effects, there
have been some pregnant patients maintained on trientine.
Walshe45 has reported on 7 patients who were treated with
trientine through 11 pregnancies. Eight healthy babies re-
sulted. Regarding the other 3, 1 baby was delivered prema-
turely and had a chromosomal defect (isochromosome X),
there was 1 miscarriage at 14 weeks, and 1 therapeutic
abortion. The infants’ ceruloplasmin levels were measured
and averaged 9.9 mg/dL, not different than controls (mean,
10.0; range, 5.6 to 18.0). However, 2 infants from Wilson’s
disease mothers did have rather low values of 3.6 and 4.6.
The urine copper values in the mothers, both ‘‘basal’’ and after
treatment, tended to increase during and immediately after
pregnancy, in 2 cases rather markedly. These results were
attributed to poor compliance.
There are also single case reports from Spain46 and from
France.47 In the Spanish case, a 22-year-old woman with






Zinc Dose at End
of Pregnancy1 2 3 4 5 6 7 8 9
27 50 3 3 = = 25 3 3 = = = = = = 25 3 3
50 3 3 25 3 3 = = = = = = = = 25 3 3
32 50 3 3 = = 25 3 2 = = = 50 3 3 = = 50 3 3
50 3 3 = = 25 3 3 = = = = = = 25 3 3
34 50 3 3 = 25 3 3 = = = = = = = 25 3 3
38 50 3 3 = = = = = 50 3 4 = = = 50 3 4
41 25 3 3 = = = = = = = = = 25 3 3
45 50 3 3 25 3 2 = = = = = = = = 25 3 2
50 3 2 25 3 3 = = = = = = = = 25 3 3
49 50 3 3 = = 25 3 3 = = = = = = 25 3 3
25 3 3 = = = 25 3 1 = = = = = 25 3 1
50 3 2 50 3 2
52 50 3 3 = = 25 3 3 = = = = = = 25 3 3
25 3 3 = = = = = = = = = 25 3 3
57 50 3 2 = = = 25 3 3 = = = = = 25 3 3
70 50 3 3 = = = = = = = = = 50 3 3
50 3 3 = = = = = = = = = 50 3 3
86 50 3 3 = = 50 3 4 = = = = = = 50 3 4
113 25 3 3 = = = = = = = = = 25 3 3
25 3 3 = = = = = = = = = 25 3 3
130 25 3 2 = = 25 3 3 = = = = = = 25 3 3
172 50 3 3 = = = = = = = = = 50 3 3
173 50 3 3 = = = = = = = = = 50 3 3
180 50 3 3 = = = = = = = = = 50 3 3
204 50 3 3 = = = = = = = = = 50 3 3
312 Pen = 25 3 3 = = = = = 50 3 3 = 50 3 3
314 Pen = 25 3 3 = = = = = = = 25 3 3
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presymptomatic Wilson’s disease was treated with trientine
(1.0 g/d) during her pregnancy. Trial of labor induction at 42
weeks failed, and a cesarean section had to be performed,
with delivery of a healthy baby. Liver function was unchanged
in the mother during and after pregnancy. The French case
was a 20-year-old pregnant patient who had presented with
severe liver disease at age 15. She had improved nicely on
trientine therapy and was continued on this drug (0.9 g/d)
during pregnancy. A healthy baby was delivered at 42 weeks.
Liver function in the mother did not change during preg-
nancy.
In summary of trientine, it appears to adequately protect
the mother’s health, and in a limited number of live births (a
total of 11), only one major abnormality (isochromosome X)
has been reported. However, trientine is teratogenic in
animals.41,42
We decided to evaluate zinc therapy during pregnancy in
Wilson’s disease patients, first because our extensive clinical
research with zinc in the process of getting it approved by the
FDA for maintenance therapy gave us reassurance that it
would protect the mother’s health, and second, zinc is not
teratogenic in animal studies.43 Our data here do provide
ample evidence that the mother’s health is protected by zinc
therapy. Although urine copper values occasionally were
elevated (Table 2), no adverse effects on liver or neurological
function were found (Table 4).
With respect to the fetal outcome, we had 2 congenital
defects in a total of 26 live births, a rate of 7.7% (Table 5). The
rate for major and minor congenital defects in the population
as a whole is about 4% (data from March of Dimes web site).
Whether with larger numbers the rate of defects found in
zinc-treated pregnancies will equal the general population, or
be higher, remains to be seen. The expected rate for any single

















27 1 and 2 5/94, 5/96 10/93 1.3 4.6 41 38
1/98 1.1 4.6 103 58
32 1 6/86 7/85 0.4 4.0 134 77
7/87 0.5 4.1 147 77
2 5/90 9/88 0.2 4.3 85 51
9/92 0.5 3.9 112 72
34 1 7/91 3/90 0.2 4.0 42 27 3/90 1 3/90 2
11/91 0.4 3.6 56 19 10/93 1 11/91 2
45 1 8/87 10/86 0.6 4.4 26 19
10/87 1.0 4.7 37 33
2 6/90 10/88 0.5 4.7 21 27
9/90 0.5 3.9 21 21
49 1 5/89 10/86 0.3 3.8 30 19 11/86 2
5/90 0.4 3.1 25 15 5/90 2
2 1/94 6/92 0.7 3.4 39 29 6/92 2 6/92 2
5/95 0.8 4.0 52 38 7/98 3 7/98 2
52 1 and 2 10/89, 1/91 4/87 0.2 4.0 16 13 1/88 7 1/88 2.5
3/91 0.3 4.2 24 25 1/93 4.5 1/93 2.5
57 1 7/92 11/91 1.4 4.7 31 30
12/92 1.2 4.1 28 —
70 1 6/91 9/89 0.2 2.8 15 24
10/92 0.3 3.3 — 33
113 1 6/97 6/95 0.5 — 36 20
8/97 0.7 3.8 41 26
312 1 5/95 10/94 0.2 4.5 — —
11/97 0.5 4.3 61 31
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase.













27 1 Normal Baby 0.108 8
2 Normal Baby 0.163 2
32 1 Normal Baby 0.149 3
2 Normal Baby 0.094 9
34 1 Normal Baby 0.140 4
38 1 Normal Baby — —
41 1 Normal Baby 0.074 16
45 1 Normal Baby 0.093 10
2 Normal Baby 0.070 18
49 1 Normal Baby 0.087 11
2 Normal Baby 0.110 7
52 1 Normal Baby 0.062 19
2 Normal Baby 0.084 12
57 1 Heart defect requiring
surgery at 6 mo
0.054 21
70 1 Normal Baby 0.140 5
2 Normal Baby — —
86 1 Normal Baby 0.045 23
113 1 Microcephalic baby that
died 1 hour after birth
0.071 17
2 Normal Baby 0.082 13
130 1 Normal Baby 0.115 6
172 1 Normal Baby 0.077 14
173 1 Normal Baby 0.061 20
180 1 Normal Baby 0.051 22
204 1 Normal Baby 0.075 15
312 1 Normal Baby 0.212 1
314 1 Normal Baby — —
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major defect is quite low, for example, 1 in 8,000 for
anencephaly. It is of interest to note that Bumah et al.48 have
reported that low serum copper concentrations in pregnant
women during midgestation is a risk factor for anencephaly.
The women in their report were, of course, not Wilson’s
disease patients, but the concordance with our one case of
microcephaly bears watching. Our single case of a specific
major defect does not provide a rate, and thus our case of
microcephaly should only be noted at this point. If repeated
again (prior to several thousand cases) it may become
meaningful.
Based on animal studies, there is reasonably good evidence
that a major factor in the production of teratogenicity by
penicillamine and trientine is copper deficiency in the
fetus.49,50 It is possible that the major risk of teratogenicity in
Wilson’s disease pregnancies is overtreatment, reducing the
copper level too low in the mother, and thereby affecting the
fetus. If so, all anticopper treatments the mother might take
could have some risk of teratogenicity, because of the risk of
overtreatment. If this reasoning is correct, the physician
should perhaps aim for reasonable but not tight control of the
mother’s copper status during pregnancy. In this connection it
is of interest that when we average the 24-hour urine copper
values during pregnancy in the 23 patients on whom we have
data from in Table 2, the 2 patients whose babies had birth
defects (patients 113 and 57) ranked near the bottom (17th
and 21st, respectively) in urine copper values (Table 5).
Another factor to consider is the manner in which the drug
exerts its anticopper effect. Both penicillamine and trientine
are chelators that function by combining with copper and
increasing its urinary excretion. Therefore, there is a built in
‘‘pulsatile’’ nature to this therapy. An oral dose is given, and as
the drug builds up in the blood stream, it decreases the level
of readily available copper because of copper chelation, with
the lowest level of available copper being reached as the drug
level hits its peak after each dose. These ‘‘troughs’’ in
availability of copper in the mother’s blood would be ex-
pected to be replicated in fetal blood, and if they happen to be
low enough, and perhaps occur at critical times in fetal
development when a higher level of copper is required, be
causative of defects.
Zinc, on the other hand, has a unique mechanism of action
among anticopper agents. Zinc acts on the intestinal cell to
block absorption of copper. Zinc therapy induces intestinal
cell metallothionein, which has a high affinity for copper.
Copper coming into the intestinal cell is bound to metallothio-
nein, preventing its serosal transfer. As intestinal cells slough
into the lumen of the bowel with about a 6-day turnover time,
they take the contained metallothionein-copper complex
with them, and the copper is excreted into the stool. This
mechanism not only functions with food copper, but with the
large amounts of endogenously secreted copper that are part
of salivary, gastric, and other gastrointestinal secretions.
Thus, the patient is put into a negative copper balance with
zinc therapy, and copper stores are gradually depleted. This
mechanism would not be expected to produce troughs in
blood copper availability, but rather to possibly blunt ‘‘peaks’’
of blood copper after mealtime. This ‘‘leveling’’ of blood
copper levels, as opposed to peaks and troughs might be
better physiologically for the fetus, and offer at least a
theoretical advantage of zinc therapy.
We have recently reported extensive follow-up (up to 10
years) data on 141 Wilson’s disease patients treated with zinc
alone as maintenance therapy.27 The general conclusion of
that study was that zinc was a completely effective, nontoxic,
treatment for Wilson’s disease. The only side effect we have
encountered is occasional gastric discomfort. Zinc must be
taken away from food to be fully effective, and the zinc
acetate capsules are sometimes irritating to the stomach. In
such patients we recommend taking the first dose at mid-
morning rather than on first arising. If problems continue,
the troublesome doses can be taken with a small amount of
protein, such as lunch meat, cheese, or jello. Protein inter-
feres with zinc action the least of all foods.
In our long follow-up study, we did find that therapy
compliance was a problem.27 Approximately 10% of patients
exhibited chronic compliance problems, (easily detected by a
drop in the urine zinc below expected values), and almost a
third of patients had occasional noncompliance episodes. It is
likely that some of the elevated urine copper values we
observed in this study (Table 2) are also caused by poor
compliance.
In terms of dose of zinc to use during pregnancy, our
tentative recommendations are to use the standard dose of 50
mg taken 3 times daily (50 3 3) for patients whose 24-hour
urine copper values generally are over 0.1 mg. However, for
patients whose 24-hour urine copper values are generally
under 0.1 mg, 25 mg taken 3 times daily (25 3 3), or even
lower doses, might be considered. Obviously, patients’ urine
copper (and zinc) levels should be monitored during preg-
nancy, and if the copper values get too high or too low,
compliance evaluated and adjustments in zinc dose should be
made if necessary. These recommendations are, of course,
only tentative until more experience is gained.
In summary, we believe zinc is a reasonable choice for
pregnant Wilson’s disease patients. It is effective and gener-
ally well tolerated. The mother’s health is protected during
pregnancy. The pregnancy outcome data (Table 4), although
limited, indicate a rate of birth defects of 7.7%, only slightly
higher than the general population risk (4%). Penicillamine
is clearly a poor choice for the pregnant Wilson’s disease
patient because of its relatively high risk of teratogenicity.
Limited data on trientine so far have shown 1 major
abnormality in 11 live births, a 9% rate. As more data come in
for trientine and for zinc, a clearer picture should emerge as
to which (if either) is a superior therapy during pregnancy.
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